Director Mark Demilio sold 2,254 shares of RH in a January 14 filing, generating proceeds of $495,880. Following the sale, he holds 19,962 shares, a 10.15% reduction in his stake valued at approximately $4.39 million. The filing with the SEC underscores ongoing insider profit-taking and may prompt investors to reassess insider confidence in near-term prospects.

In its December quarter, RH reported revenue of $883.81 million, up 8.9% year-over-year and essentially matching analyst forecasts of $883.65 million. However, earnings per share came in at $1.71, missing consensus by $0.42 and driving a net margin of 3.22%. Return on equity remained deeply negative at 161.72%, reflecting high leverage and pressure on profitability despite top-line growth.

Analyst views on RH are divided: Morgan Stanley set a $275 target citing sustained revenue growth and potential multiple rerating, while the median target across 21 firms sits near $227 following recent downgrades by Goldman Sachs, Barclays and Stifel. Nine analysts rate the stock a buy, eight a hold and four a sell, resulting in a consensus ‘Hold’ rating but with a wide six-month range of targets.

Institutional investors maintain a dominant 90.17% ownership stake in RH. Notable shifts include a 713.3% increase by Clearstead Advisors and new positions by BNP Paribas Asset Management and Harvest Fund Management. At the same time, large buys and sells across multiple funds suggest mixed conviction on the company’s fundamentals, potentially amplifying stock volatility in the coming quarters.